Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
AACR 2026: Moderna, Revolution, Zymeworks and BeOne showcase new data
The AACR 2026 annual meeting saw new data presented from Moderna, Revolution Medicines, Zymeworks, and BeOne. Moderna’s experimental antigen therapy mRNA-4359 showed an 83% overall response rate in melanoma patients when combined with Keytruda. Revolution Medicines updated its Phase 1 data for lung cancer drug zoldonrasib, demonstrating a 52% confirmed ORR and 11.1 months median progression-free survival. Zymeworks presented “encouraging but early” data for zanidatamab in early-stage HER2-positive breast cancer, suggesting it could reduce the need for chemotherapy, while BeOne’s Tevimbra combinations in head and neck squamous cell carcinoma did not show added benefit over monotherapy.